MDCX
Medicus Pharma·NASDAQ
--
--(--)
--
--(--)
6.78 / 10
Outperform
Fund flow metrics are encouraging with a 7.47/10 score, indicating robust capital inflow despite negative trends in block and medium sizes. Analyst coverage is limited but overwhelmingly bullish (Strong Buy at 100%), yet historical win rates are only 40%, tempering conviction. Together, positive fund flows and bullish analyst stance partially offset technical and fundamental weaknesses.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-12-15
InstitutionD. Boral Capital
Times predicted20
Historical Win Rate40.0%
What is the analyst consensus for MDCX?
- MDCX holds a Bullish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 6.78/10 (Outperform).
